From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak
| Autor: | Nicole Bohic, Eva Hong, Ludovic Lemée, Daniel Floret, Jacques Benichou, Daniel Lévy-Bruhl, Isabelle Parent du Châtelet, Gilles Berthelot, Jean-Philippe Leroy, Valérie Delbos, Nathalie Massy, Muhamed-Kheir Taha, Corinne Ruckly, Martin Révillion, Ala-Eddine Deghmane, Isabelle Morer, François Caron, Myriam Blanchard |
|---|---|
| Přispěvatelé: | Service des Maladies Infectieuses et Tropicales [Hôpital Charles Nicolle, Rouen], Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Veille Sanitaire (INVS), Cellule interrégionale d'épidémiologie Antilles-Guyane [CIRE], Agence Régionale de la Santé (ARS), Centre Régional de Pharmacovigilance [Hôpital Charles Nicolle, Rouen], Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS), AFSSAPS, Comité technique des vaccinations, Haut Conseil de la Santé Publique (HCSP), Centre National de Référence des Méningocoques et Haemophilus influenzae - National Reference Center Meningococci and Haemophilus influenzae (CNR), Institut Pasteur [Paris], Cellule Interrégionale d’épidémiologie de l’InVS, Institut de Veille Sanitaire (CIRE), Centre hospitalier de Dieppe, Groupe de Recherche sur les Antimicrobiens et les Micro-Organismes (GRAM 1.0), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU), Unité de biostatistiques [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), French Ministry of Health, Martin, Marie, Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP) |
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Pediatrics
Vaccination schedule Neisseria meningitidis Serogroup B medicine.disease_cause MESH: Meningococcal Infections Disease Outbreaks MESH: Meningococcal Vaccines Cohort Studies 0302 clinical medicine [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases MESH: Antibodies Bacterial Longitudinal Studies Poisson Distribution 030212 general & internal medicine MESH: Incidence MESH: Disease Outbreaks MESH: Longitudinal Studies MESH: Cohort Studies 0303 health sciences education.field_of_study Incidence Neisseria meningitidis Incidence (epidemiology) Antibodies Bacterial MESH: Infant 3. Good health Vaccination Infectious Diseases Child Preschool Cohort [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases France Bacterial Outer Membrane Proteins medicine.medical_specialty Population Meningococcal Vaccines Meningococcal disease Mass Vaccination MESH: Poisson Distribution 03 medical and health sciences [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology MESH: Neisseria meningitidis Serogroup B medicine Humans education MESH: Humans 030306 microbiology business.industry MESH: Bacterial Outer Membrane Proteins MESH: Child Preschool Infant Outbreak medicine.disease Meningococcal Infections MESH: France [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie MESH: Mass Vaccination [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology business |
| Zdroj: | The Lancet Infectious Diseases The Lancet Infectious Diseases, New York, NY : Elsevier Science ; The Lancet Pub. Group, 2001-, 2011, 11 (6), pp.455-463. ⟨10.1016/S1473-3099(11)70027-5⟩ The Lancet Infectious Diseases, 2011, 11 (6), pp.455-463. ⟨10.1016/S1473-3099(11)70027-5⟩ |
| ISSN: | 1473-3099 1474-4457 |
| DOI: | 10.1016/S1473-3099(11)70027-5⟩ |
| Popis: | Erratum in Lancet Infect Dis. 2011 Jul;11(7):495.; International audience; BACKGROUND:Outer-membrane-vesicle vaccines for meningococcal B outbreaks are complex and time consuming to develop. We studied the use of already available vaccine to control an outbreak caused by a genetically close strain.METHODS:From 2006 to 2009, all individuals younger than 20 years living in the region of Normandy, France, in which an outbreak caused by a B:14:P1.7,16 strain occurred, were eligible to receive MenBvac, a Norwegian vaccine designed 20 years earlier against a strain sharing the same serosubtype (B:15:P1.7,16). The immunogenicity (in a randomly selected cohort of 400 children aged 1-5 years), safety, and epidemiological effect of the vaccination were assessed.FINDINGS:26,014 individuals were eligible to receive the vaccine. Shortage of vaccine production prompted start of the campaign in the highest incidence groups (1-5 years). 16,709 (64%) received a complete vaccination schedule of whom 13,589 (81%) received a 2+1 dose schedule (week 0, week 6, and month 8). At 6 weeks after the third dose, of 235 vaccinees for whom samples were available, 206 (88%) had a seroresponse, and 108 (56 %) of 193 had a seroresponse at 15 months. These results were similar to those described for tailor-made vaccines and their homologous strain. Only previously described adverse effects occurred. The incidence of B:14:P1.7,16 cases decreased significantly in the vaccine targeted population after the primary vaccination period (from 31·6 per 100,000 to 5·9 per 100,000; p=0·001).INTERPRETATION:The ready-to-wear approach is reliable if epidemic and vaccine strains are genetically close. Other meningococcal B clonal outbreaks might benefit from this strategy; and previously described outer-membrane-vesicle vaccines can be effective against various strains. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|